Under the terms of the agreement, X-Chem is expected to get an upfront and research payments, success-based discovery milestones, and technology access fees from Roche.
Roche is expected to posses the development and commercialisation rights over any product arising from the collaboration, and X-Chem is expected to receive development milestones and royalties based on worldwide sales of the therapeutic products developed by Roche.
Richard Wagner, president and CEO of X-Chem, said: “Entering into our first alliance with a partner such as Roche is exciting for our company. The program that we are developing is expected to establish drug discovery capabilities in the industry.”